Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PhRMA’s “Reality Check”

Executive Summary

Pharmaceutical Research & Manufacturers of America President Alan Holmer is embarking on a 45-city media tour as part of the trade association's effort "to ramp up the public relations effort of the pharmaceutical industry." The first stop is two days in Tampa that include four speeches, three radio interviews and two editorial board meetings along with other press events. The "Reality Check" tour will "set the record straight" about the value of pharmaceuticals, PhRMA declares. The association board approved the more aggressive media outreach campaign in November (1"The Pink Sheet" Dec. 16, 2002, p. 20)...

You may also be interested in...



PhRMA Vows To “Re-Shape” Policy Debate; Will Reach Out To Critics

The Pharmaceutical Research & Manufacturers of America plans to make peace overtures to some of its critics within the healthcare sector as part of a new image strategy heading into 2003

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS041104

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel